This EVERSANA point of view paper discusses how large pharmaceutical companies can modernize commercialization strategies to remain competitive in an evolving life sciences market. It highlights four priorities: increasing organizational agility, adopting single-partner outsourcing models, expanding revenue through established brands and in-licensing, and strengthening digital capabilities. The paper argues that traditional commercialization models are no longer suited for complex therapies targeting smaller patient populations and that integrated, data-driven approaches can reduce costs, improve efficiency, accelerate market access, and enhance patient engagement. It concludes that scalable commercialization partnerships, digital innovation, and flexible operating models will enable pharm

Join for free to read